You are here:

Archived: Adefovir dipivoxil (Hepsera®)


Not recommended for use within NHS Scotland.


Adefovir dipivoxil may offer an alternative, convenient oral therapy for the treatment of chronic hepatitis B. However, there are limited data to assess the efficacy of adefovir dipivoxil relative to other treatments in treatment-naïve patients. Moreover there are only limited data on sustained response rates and the optimum duration of therapy remains to be determined. The cost-effectiveness of adefovir dipivoxil in managing chronic hepatitis B has not been addressed by the company in this submission. The current information suggests that it is almost three times more costly than its principal competitor without evidence of commensurate benefit. The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Adefovir dipivoxil (Hepsera®)
SMC Drug ID: 54/03
Manufacturer: Gilead Sciences Ltd
Indication: Chronic hepatitis B
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 August 2003

Current Advice

Resubmission 9 May 2005